Kidney transplant rejection trial pulled before it began

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged 18 -75 years. * Patients having received a kidney transplant from a living or deceased donor * Patients with stable renal function * Sensitized patient with at least one anti-HLA class II DSA (MFI \> 1000) within the first 3 months. * Adequate 3-month-protocol biopsy exhibiting microcirculation inflammation defined by glomerulitis Banff score (g) superior or egal 2 and /or peri-tubular capillaritis Banff score (ptc) superior or egal 2, AND the sum of scores g + ptc superior or egal 3. * C4d positive staining on 3-month-protocol biopsy * Adequate 3-month-protocol biopsy exhibiting limited scarred areas as defined as IF/TA score (ci + ct) inferior or egal 2 and no or minimal transplant glomerulopathy (cg inferior or egal 1) * Patients who have given written informed consent to participate in all aspects of the study. * Females of childbearing potential must have a negative pregnancy test within 48 hours prior to the first eculizumab administration. Exclusion Criteria: * Patients with known hypersensitivity to eculizumab or drugs with similar chemical structure. * Patients having experienced and having been treated for an acute antibody-mediated rejection within the first 3 months post-transplant * Patients with multi-organ transplant * Female patients who are pregnant, lactating or of child bearing potential and not practicing an approved method of birth control. * Patients with a known malignancy or history of malignancy other than excised basal or squamous cell carcinoma of the skin * HBV, HCV or HIV-chronically infected patients * Patients with evidence of severe liver disease, including abnormal liver profile (aspartate aminotransferase \[AST\], alanine aminotransferases \[ALT\] or total bilirubin \> 3 times upper limit of normal at screening. * Patients with current severe infection. * Ongoing meningococcal infection * Patient with systemic lupus erythematosus disease and / or anti-phospholipid antibodies * Patients with any surgical or medical condition, which in the opinion of the investigator precludes enrollment in this trial * Patients who live far from the transplant center and are unable to comply with all study visits. * Long-term anticoagulation therapy or other contraindication to graft biopsies * Positive BKV viremia during the first three months post-transplant